Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled

Ryan W Smith1, Kim Downey, Michelle Gordon

  • 1Department of Medicine and Health, University College Cork, Cork, Ireland;

Insights

Inhaled corticosteroids (ICS) can cause hypothalamic-pituitary-adrenal (HPA) axis suppression in children with asthma. Regular screening for HPA axis suppression is recommended, especially for those on high-dose ICS.

Area of Science:

  • Pediatric Endocrinology
  • Respiratory Medicine
  • Pharmacology

Background:

  • Asthma management often involves inhaled corticosteroids (ICS).
  • Long-term ICS use may impact the hypothalamic-pituitary-adrenal (HPA) axis.
  • HPA axis suppression is a potential concern in children receiving ICS therapy.

Purpose of the Study:

  • To investigate the prevalence of HPA axis suppression in pediatric asthma patients using ICS.
  • To identify risk factors associated with HPA axis suppression in this population.

Main Methods:

  • A cohort of 214 children with asthma on ICS was studied.
  • HPA axis suppression was assessed via morning serum cortisol and ACTH stimulation tests.
  • Clinical and demographic data were collected for analysis.

Main Results:

  • HPA axis suppression was detected in 9.3% of the children studied.
  • Increased ICS dosage correlated significantly with higher odds of HPA axis suppression.
  • Suppression was observed in children using 200-500 μg/day of ICS, with no prediction by drug type or duration.

Conclusions:

  • Laboratory evidence confirms HPA axis suppression in children treated with ICS for asthma.
  • Routine screening for HPA axis suppression is advised for children on high-dose ICS (>500 μg/day).
  • Screening may also be beneficial for children on medium-dose ICS.
Abstract

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Cushing Syndrome II: Pathophysiology01:19

Cushing Syndrome II: Pathophysiology

Cortisol production is normally governed by the hypothalamic–pituitary–adrenal (HPA) axis, which maintains hormonal balance through tightly regulated feedback mechanisms. Disruption of this regulatory system is central to the development of Cushing syndrome, whether the excess cortisol originates from external medications or internal pathology. Persistent cortisol elevation alters metabolism, immune function, and endocrine signaling, producing the characteristic clinical features of the...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...
Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...